Oral Wegovy Weight Loss Calculator

Last updated: 2025-06-01 Medically reviewed content Based on peer-reviewed research

These are estimates based on average outcomes from the OASIS 1 clinical trial. Individual results vary significantly based on genetics, diet, exercise, and metabolic factors. Consult your healthcare provider before starting or adjusting any GLP-1 medication.

What Is Oral Wegovy?

Oral Wegovy is the pill form of semaglutide, FDA-approved in December 2025 for chronic weight management. Unlike injectable Wegovy (2.4mg weekly injection), oral Wegovy is taken as a daily tablet at a maintenance dose of 25mg. It contains the same active ingredient — semaglutide, a GLP-1 receptor agonist — but uses an absorption enhancer (SNAC) to allow the peptide to survive the digestive system. In the OASIS 1 clinical trial, oral semaglutide 25mg produced approximately 14% body weight loss at 68 weeks, making it a needle-free alternative with results close to the injectable form.

Contents

How Oral Wegovy Compares to Injectable Wegovy

Both oral and injectable Wegovy contain semaglutide and are FDA-approved for chronic weight management. The key differences are how you take them, dosing frequency, and slight differences in clinical trial outcomes. Injectable Wegovy (2.4mg weekly) achieved about 15% weight loss at 68 weeks in the STEP 1 trial. Oral Wegovy (25mg daily) achieved about 14% weight loss at 68 weeks in the OASIS 1 trial. The oral form trades a small reduction in average efficacy for the major convenience of no needles.

Oral Wegovy (25mg daily pill): Approximately 14% body weight loss at 68 weeks (OASIS 1 trial). Taken daily on an empty stomach.

Injectable Wegovy (2.4mg weekly): Average 14.9% body weight loss at 68 weeks (STEP 1, N=1,961). Subcutaneous injection once per week.

Ozempic (1.0mg weekly injection): Average ~8% body weight loss at 52 weeks (SUSTAIN trials). FDA-approved for diabetes, not weight loss.

Who Should Consider the Oral Form?

Oral Wegovy may be a better fit if you have needle phobia or strong aversion to self-injection, prefer a daily routine over a weekly injection schedule, travel frequently and want to avoid carrying injection supplies, or have experienced injection site reactions with the injectable form. However, the strict fasting requirement (empty stomach, minimal water, 30-minute wait before food) makes the oral form less convenient for some patients.

Who May Prefer the Injectable Form?

Injectable Wegovy may be preferable if you have trouble with the fasting requirement, prefer once-weekly dosing over daily pills, have gastrointestinal conditions that could affect oral absorption, or want the slightly higher average weight loss seen in the STEP trials. The injectable form does not require fasting and is not affected by food or other oral medications.

Dosing Schedule for Oral Semaglutide (Oral Wegovy)

Oral Wegovy uses a gradual 16-week dose escalation to minimize gastrointestinal side effects. Each dose level is maintained for 4 weeks before increasing. Do not skip steps or accelerate the schedule without medical supervision.

Weeks 1-4: 1.5 mg once daily (starting dose)

Weeks 5-8: 4 mg once daily

Weeks 9-12: 9 mg once daily

Weeks 13-16: 14 mg once daily

Week 17 onward: 25 mg once daily (maintenance dose)

During the dose-titration phase (weeks 1-16), the primary goal is building tolerability. The most common side effects — nausea, vomiting, and diarrhea — are most likely to occur during dose increases. Significant weight loss typically accelerates after reaching the 25mg maintenance dose, though most patients begin losing weight during escalation.

Comparison to Injectable Wegovy Dose Schedule

Injectable Weeks 1-4: 0.25 mg once weekly

Injectable Weeks 5-8: 0.5 mg once weekly

Injectable Weeks 9-12: 1.0 mg once weekly

Injectable Weeks 13-16: 1.7 mg once weekly

Injectable Week 17+: 2.4 mg once weekly (maintenance dose)

Both forms share the same 16-week escalation structure, but the oral form uses higher milligram doses because oral bioavailability of semaglutide is approximately 1% — meaning only about 1% of the oral dose reaches the bloodstream. The absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) is co-formulated in the tablet to increase this absorption.

How to Take the Oral Wegovy Pill

Oral semaglutide has strict administration requirements because the peptide is fragile in the digestive environment. Following these instructions precisely is critical for the medication to work.

1. Empty stomach: Take the pill first thing in the morning, before eating or drinking anything.

2. Minimal water: Swallow the tablet with no more than 4 ounces (120 mL) of plain water only.

3. Wait 30 minutes: Do not eat, drink, or take other oral medications for at least 30 minutes after taking the pill.

4. Swallow whole: Do not split, crush, or chew the tablet.

Food, beverages (other than plain water), and other medications in the stomach reduce absorption of oral semaglutide and can make the medication less effective. The 30-minute fasting window is the minimum — longer fasting times may slightly improve absorption. If you miss a dose, skip it and take your next dose the following day at the usual time. Do not double up on doses.

Related Guide

Want a detailed, evidence-based understanding of how semaglutide works for weight loss? Our comprehensive guide covers week-by-week expected results, proper dosage protocols, managing side effects, and long-term maintenance strategies. Read the full Semaglutide Weight Loss Guide →

Learn the Difference Between Brands

Ozempic, Wegovy, and other GLP-1 medications share the same ingredient — semaglutide. But they're not always used the same way. Read the full breakdown →

Frequently Asked Questions

How much weight can I lose on oral Wegovy?

In the OASIS 1 clinical trial, participants taking oral semaglutide 25mg daily lost an average of approximately 14% of their body weight over 68 weeks, compared to about 2% with placebo. The trajectory is approximately 5% at 12 weeks, 9% at 24 weeks, 12% at 36 weeks, 13% at 52 weeks, and 14% at 68 weeks. Results depend on treatment adherence, diet, exercise, and individual metabolic factors. Some patients may lose more or less than the average.

What is the difference between oral Wegovy and injectable Wegovy?

Both forms contain semaglutide and are FDA-approved for chronic weight management. Oral Wegovy is a daily pill (maintenance dose 25mg) while injectable Wegovy is a weekly injection (maintenance dose 2.4mg). Injectable Wegovy achieved about 15% weight loss at 68 weeks in the STEP 1 trial (N=1,961), while oral Wegovy achieved about 14% in the OASIS 1 trial. The oral form requires taking the pill on an empty stomach with minimal water, 30 minutes before food — a strict requirement that the injectable form does not have.

Why are the oral and injectable doses so different?

Oral semaglutide has a bioavailability of approximately 1%, meaning only about 1% of the dose reaches the bloodstream through the digestive system. The 25mg oral maintenance dose delivers roughly the same amount of active semaglutide to the blood as the 2.4mg injectable dose. The tablet includes an absorption enhancer called SNAC that protects the semaglutide molecule and increases uptake through the stomach lining.

When was oral Wegovy FDA-approved?

The FDA approved oral semaglutide for chronic weight management in December 2025. This made Wegovy available in both injectable and oral forms. The approval was based on the OASIS 1 clinical trial, which demonstrated that oral semaglutide 25mg daily produced clinically meaningful weight loss in adults with obesity or overweight with at least one weight-related condition. Note that oral semaglutide was previously available at lower doses (Rybelsus, up to 14mg) for type 2 diabetes, but the 25mg weight-management dose is a new formulation.

Is this calculator based on real clinical trial data?

Yes. The weight loss projections are derived from the OASIS 1 (Oral Semaglutide as an Aid to weight management: a randomIzed, double-blind, placebo-controlled trial) clinical trial. The approximate trajectory used — 5% at 12 weeks, 9% at 24 weeks, 12% at 36 weeks, 13% at 52 weeks, and 14% at 68 weeks — reflects the non-linear pattern of weight loss observed in the trial, where most loss occurs in the first 36 weeks with a gradual plateau thereafter. Individual results vary based on adherence, diet, exercise, and metabolic factors.

Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.